aTyr Pharma To Present Subgroup Analysis Of Phase 3 EFZO-FIT Study Of Efzofitimod In Pulmonary Sarcoidosis At WASOG 2026 Congress; Submits Phase 3 Protocol To FDA For Efzofitimod In June

Loading news article.

aTyr Pharma To Present Subgroup Analysis Of Phase 3 EFZO-FIT Study Of Efzofitimod In Pulmonary Sarcoidosis At WASOG 2026 Congress; Submits Phase 3 Protocol To FDA For Efzofitimod In June | WAPE

aTyr Pharma To Present Subgroup Analysis Of Phase 3 EFZO-FIT Study Of Efzofitimod In Pulmonary Sarcoidosis At WASOG 2026 Congress; Submits Phase 3 Protocol To FDA For Efzofitimod In June

Article summary

Related companies

Comments —